Zentalis Pharmaceuticals' Cash Burn Rate and Its Implications for Investors

Zentalis Pharmaceuticals has a cash runway of 2.1 years with zero debt and cash worth $281m. The company reduced its cash burn by 22% during the last year but operating revenue declined by 34%. While the past is worth studying, the future is more important. Zentalis Pharmaceuticals seems to be in a good position, but it's worthwhile considering how easily it could raise more money if needed.